Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy

NCT01468350 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Cerebral Palsy (CP)

Interventions

DRUG: dalfampridine-ER 10mg
OTHER: Placebo

Sponsor

Acorda Therapeutics